Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
about
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolismNovel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative ManagementPeriprocedural imaging and outcomes after catheter ablation of atrial fibrillation.Cost analysis of periprocedural imaging in patients undergoing catheter ablation for atrial fibrillation.Left atrial appendage devices for stroke prevention in atrial fibrillation.The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey.National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiariesCurrent issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism.Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative dataPredictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis.Mexican Americans with atrial fibrillation have more recurrent strokes than do non-Hispanic whites.A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study.Stroke in atrial fibrillation--hope on the horizon?Racial/ethnic disparities in access to physician care and medications among US stroke survivorsPhysician's fear of anticoagulant therapy in nonvalvular atrial fibrillation.Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: trends by age, sex, and race, 1992-2010.Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?Atrial fibrillation: current knowledge and future directions in epidemiology and genomics.Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCXAtrial fibrillation ablation and left appendage closure in heart failure patientsWarfarin usage among elderly atrial fibrillation patients with traumatic injury, an analysis of United States Medicare fee-for-service enrolleesPeer education for secondary stroke prevention in inner-city minorities: design and methods of the prevent recurrence of all inner-city strokes through education randomized controlled trialAddressing Stroke Risk Factors in Black and White Americans: Findings from the National Health and Nutrition Examination Survey, 2009-2010Pharmacotherapy in Medicare beneficiaries with atrial fibrillation.The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patientsPotential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy?Newer anticoagulants for non-valvular atrial fibrillation.Towards open information management in health careAtrial Fibrillation and Race - A Contemporary Review.Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old AgentsApixaban in patients with Atrial Fibrillation: A Systematic ReviewWarfarin and atrial fibrillation: from ideal to real the warfarin affaire.Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study.Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administrationNovel anticoagulants for atrial fibrillation: a critical appraisal.
P2860
Q26746233-9C45F6ED-0EB3-415C-976C-2BB9DA4DC0D2Q26801895-0D6B71FE-D84D-44D5-80A9-4A7EB27C50EBQ27317373-372ED59A-0D21-49DE-889D-27B23B6E7E70Q30406783-1D1AFFEA-E0F9-4526-84BC-AE0D4A37BAD6Q30457989-4CA41312-DD4F-4FA8-9A9B-41973C10EBF5Q33384911-69BC7DEB-6FE8-4C66-B7D2-7E13121CA437Q33553982-91F53213-0FE8-4AA5-BE7B-40185A84619CQ33755738-70164E47-2D8E-4EA1-89F5-B568EC3286A6Q33828157-73393ECE-1676-42C8-9992-A6C498F62363Q33936087-A716003A-55D1-4F74-94AF-11D8242B5A71Q34133867-3A386F92-CEF1-41DB-9568-A9CE8C9A4272Q34150474-B1DDE196-F5EB-457A-89A7-0708C23E3F94Q34164148-2919DE2A-0FB8-48F7-BED9-0739062D7FC7Q34317469-ACAACC6B-35C1-4CA8-8976-25E8A5231D5DQ34333317-6AB49EB5-B3B3-430D-BEB3-94BA229B07B6Q34536283-42659938-F3AC-458C-89C6-3EB417982F9CQ34551073-A6BED9A9-320A-4179-80E8-3DF524709908Q34931005-D3FD0850-34C3-4A98-B418-2E4366A7035BQ35021837-87F8C350-904D-4E4E-9B77-71BCF314A09FQ35062047-B62C9C96-F4B7-46C3-8F0A-58FB73C87564Q35526930-9AE4F5A1-C851-4F3F-B714-705DBDE63275Q35654365-A8E0C334-26C6-4081-8D5F-66E4FED87D53Q35706472-38A1A080-DB87-44B1-921A-932351BC8685Q35755766-69BF8998-5BAF-4C5D-B206-897697A2626AQ36062288-4C8E978D-6150-4F33-9B4E-D979D626EC3CQ36129396-48073FDF-B9C9-4758-8BE5-3EF73562C6DDQ36537503-944E5AA2-B1A5-4D5D-83C2-F7D3516DF20FQ36838560-E8A3D24C-050E-4214-891E-23554AC8A568Q37014482-A06BC68E-A8EF-48F2-930E-47A33CE69B90Q37108889-454F3368-762F-424E-B9EA-EFF56DF22CF8Q37115353-9E3246BD-7FE0-40E5-9999-AF3A6CA02AA5Q37148738-31A814B0-7FA6-4F4F-9C56-BD411D5B61ABQ37153551-14457DB5-DA66-44DE-A8DB-C9164A14D5B7Q37274009-BDA03233-F9D6-421B-9B28-73445B9FBD16Q37495788-451A6950-0D72-41C4-9508-883589513CA2Q37495983-8B97C39C-791D-454E-8ABE-B251429DF55AQ37607493-0EF0436D-8566-4B46-A951-993D93A5C916Q37696652-02FB249C-6C28-40CD-9824-D7BF11B6D44FQ37738786-0AA725A9-23E5-4B7D-986E-F6C5B30D1528Q37946861-00B86C3A-1AFA-4272-B8EC-A7480E20991E
P2860
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
@en
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
@nl
type
label
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
@en
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
@nl
prefLabel
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
@en
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
@nl
P2093
P1433
P1476
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
@en
P2093
Brian F Gage
David S Nilasena
Elena Birman-Deych
P304
P356
10.1161/01.STR.0000208294.46968.A4
P407
P577
2006-03-09T00:00:00Z